GlassScriptPhysician profile
Kevin Sorensen
NPI 1144680141
$18,390.22
in general payments reported to CMS, 2019-2025
60 companies · $3,542 in 2025
The $3,542 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,236 · 2021: $4,428 · 2022: $3,508 · 2023: $2,704 · 2024: $2,971 · 2025: $3,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,217.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,042.52 | 2020-2025 | Vraylar, Linzess, Ubrelvy |
| Novo Nordisk INC | $2,040.21 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,749.12 | 2020-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $1,318.52 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,116.14 | 2020-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $883.12 | 2020-2025 | Farxiga, Fasenra, Airsupra |
| Corcept Therapeutics | $816.58 | 2020-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $619.69 | 2021-2025 | Jardiance, Ofev, Jascayd |
| Lilly USA, LLC | $555.56 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Daiichi Sankyo INC. | $498.83 | 2020-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $414.69 | 2020-2024 | Belsomra, Gardasil 9, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $413.87 | 2022 | |
| Glaxosmithkline, LLC. | $396.37 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $260.21 | 2020-2021 | |
| Eisai INC. | $260.13 | 2020-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sorensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.